Skip Navigation


JAC Advance Access originally published online on October 13, 2007
Journal of Antimicrobial Chemotherapy 2007 60(6):1258-1263; doi:10.1093/jac/dkm384
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
60/6/1258    most recent
dkm384v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Witte, W.
Right arrow Articles by Nuebel, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witte, W.
Right arrow Articles by Nuebel, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006

Wolfgang Witte*, Birgit Strommenger, Christa Cuny, Dagmar Heuck and Ulrich Nuebel

Robert Koch Institute, Wernigerode Branch, 38855 Wernigerode, Germany

Received 29 March 2007; returned 22 June 2007; revised 11 September 2007; accepted 12 September 2007

* Corresponding author. Tel: +49-3943-679246; Fax: +49-3943-679317; E-mail: wittew{at}rki.de

Objectives: The aim of this paper is to attribute Panton-Valentine leucocidin (PVL)-positive methicillin-resistant Staphylococcus aureus (MRSA) to clonal lineages by molecular typing with special reference to isolates exhibiting spa type t008/multilocus sequence type (MLST) ST8 [widely disseminated in the USA as ‘community-associated MRSA (caMRSA) USA300’].

Methods: PVL-positive MRSA (n = 117) were detected among 4815 MRSA sent to the German National Reference Laboratory for typing. These isolates were analysed by PFGE, spa typing, multilocus sequence typing, grouping of SCCmec elements and PCR detection of arcA, msr(A), mph(B) and the ≥6 AT repeat unit in the SACOL0058 sequence.

Results: Among the 117 isolates, 80 exhibited spa type t044 (corresponding to MLST ST80) and 23 exhibited spa type t008/MLST ST8. Other spa types were sporadically represented. Further characterization of isolates exhibiting t008/ST8 by PCR [arcA, msr(A), mph(B), ≥6 AT repeat signature] indicates the arrival of caMRSA ‘USA300’ in Central Europe.

Conclusions: caMRSA ST80 still predominate; however, caMRSA ST8 exhibiting the characteristics of the ‘USA300’ clone became the second most frequent. Routine detection of this clone in clinical bacteriology can be easily performed by PCR.

Keywords: community MRSA , genotyping , molecular markers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
T. Takano, W. Higuchi, T. Otsuka, T. Baranovich, S. Enany, K. Saito, H. Isobe, S. Dohmae, K. Ozaki, M. Takano, et al.
Novel Characteristics of Community-Acquired Methicillin-Resistant Staphylococcus aureus Strains Belonging to Multilocus Sequence Type 59 in Taiwan
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 837 - 845.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.